Cambridge immunotherapy firm Jounce plots $75M IPO – Boston Business Journal
Boston Business Journal |
Cambridge immunotherapy firm Jounce plots $75M IPO
Boston Business Journal Cambridge-based Jounce Therapeutics, which struck a massive deal with Celgene earlier this year to develop cancer drugs, said on Friday that it now plans to raise up to $75 million in an initial public offering. Jounce, which was launched by Third Rock … US IPO Weekly Recap: Out with the old, in with the new |
